Gastroenterology at Renji Hospital Shanghai | CMCS

China's Premier Center for Digestive & Liver Disease

The Department of Gastroenterology at Renji Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of China's most distinguished and highest-volume gastroenterology centers, with a national and international reputation for excellence in inflammatory bowel disease, autoimmune liver disease, advanced endoscopy, gastrointestinal motility, and the management of complex digestive conditions. The department is a national key clinical specialty and one of China's leading gastroenterology research centers, with landmark contributions to IBD management, liver disease, and endoscopic techniques that have shaped clinical practice across China and beyond.

For international patients with Crohn's disease, ulcerative colitis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or a complex gastrointestinal condition — Renji Hospital's gastroenterology department offers an unparalleled combination of clinical expertise, endoscopic capability, and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at Renji Hospital.

About the Department

Renji Hospital's gastroenterology department is a national key clinical specialty operating dedicated gastroenterology inpatient wards, a comprehensive outpatient gastroenterology clinic, a state-of-the-art endoscopy center, an IBD center, an autoimmune liver disease clinic, a motility laboratory, a capsule endoscopy service, and works in close collaboration with hepatobiliary surgery, liver transplantation, pathology, and radiology through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading gastroenterology journals including Gastroenterology, Gut, Journal of Hepatology, Hepatology, Inflammatory Bowel Diseases, and Endoscopy.

Conditions Treated

Inflammatory Bowel Disease (IBD)

Renji Hospital's IBD center is one of China's most experienced, managing one of the largest IBD patient cohorts in the country:

• Crohn's Disease — Treat-to-target strategy with mucosal healing as goal; anti-TNF therapy (infliximab, adalimumab); ustekinumab; vedolizumab; risankizumab; ozanimod; JAK inhibitors (upadacitinib) for moderate-severe CD; therapeutic drug monitoring (TDM) for biologic optimization; exclusive enteral nutrition (EEN) for induction; stricture dilation; fistula management; surgical coordination for complications
• Ulcerative Colitis — 5-ASA for mild-moderate UC; infliximab and adalimumab; vedolizumab; ustekinumab; tofacitinib and upadacitinib for moderate-severe UC; ozanimod; etrasimod; mirikizumab; colectomy coordination for medically refractory UC
• IBD Complications — Stricture endoscopic balloon dilation; fistula management; perianal disease; IBD-related arthropathy and uveitis; primary sclerosing cholangitis overlap; colorectal cancer surveillance
• Biologic Therapeutic Drug Monitoring — Proactive TDM for infliximab and adalimumab; dose optimization based on trough levels and anti-drug antibody testing; reactive TDM for secondary loss of response
• Fecal Microbiota Transplantation (FMT) — For recurrent Clostridioides difficile infection; investigational for UC; one of China's most experienced FMT programs

Autoimmune Liver Disease

• Autoimmune Hepatitis (AIH) — Prednisolone + azathioprine induction and maintenance; mycophenolate mofetil for azathioprine-intolerant patients; budesonide for mild AIH without cirrhosis; calcineurin inhibitors for refractory AIH; liver transplantation coordination for acute liver failure and end-stage disease
• Primary Biliary Cholangitis (PBC) — Ursodeoxycholic acid (UDCA) as first-line; obeticholic acid (OCA) for UDCA non-responders; bezafibrate; elafibranor; seladelpar; linerixibat for pruritus; liver transplantation for end-stage PBC
• Primary Sclerosing Cholangitis (PSC) — UDCA; endoscopic management of dominant strictures (ERCP with balloon dilation and stenting); cholangiocarcinoma surveillance; IBD-PSC overlap management; liver transplantation coordination
• AIH-PBC Overlap Syndrome — Combined UDCA + immunosuppression
• Drug-Induced Liver Injury (DILI) — Causality assessment (RUCAM scale); drug withdrawal; corticosteroids for immune-mediated DILI; N-acetylcysteine for paracetamol DILI
• Non-Alcoholic Fatty Liver Disease (NAFLD/MASLD) — Lifestyle intervention; resmetirom (THR-β agonist) for MASH with fibrosis; semaglutide; lanifibranor; obeticholic acid
• Alcoholic Liver Disease — Alcohol cessation support; prednisolone for severe alcoholic hepatitis; pentoxifylline; nutritional support
• Viral Hepatitis — HBV: tenofovir, entecavir, bulevirtide for HDV; HCV: sofosbuvir/velpatasvir, glecaprevir/pibrentasvir (pan-genotypic DAA therapy)
• Liver Cirrhosis Complications — Ascites management; spontaneous bacterial peritonitis (SBP) prophylaxis; hepatic encephalopathy; variceal bleeding (endoscopic band ligation, TIPS coordination); hepatorenal syndrome (terlipressin, norepinephrine)

Advanced Endoscopy

Renji Hospital's endoscopy center is one of the most advanced in China, offering the full range of diagnostic and therapeutic endoscopic procedures:

• Endoscopic Submucosal Dissection (ESD) — En bloc resection of early gastric, esophageal, and colorectal cancers and large polyps; one of China's highest-volume ESD programs
• Endoscopic Mucosal Resection (EMR) — For flat and sessile polyps; underwater EMR for difficult lesions
• Endoscopic Full-Thickness Resection (EFTR) — For subepithelial tumors and difficult polyps
• Submucosal Tunneling Endoscopic Resection (STER) — For subepithelial tumors of the esophagus and stomach
• Per-Oral Endoscopic Myotomy (POEM) — For achalasia and other esophageal motility disorders; one of China's most experienced POEM programs
• Endoscopic Ultrasound (EUS) — Diagnostic EUS for pancreatic, biliary, and subepithelial lesions; EUS-guided fine needle aspiration (FNA) and biopsy (FNB); EUS-guided celiac plexus block; EUS-guided drainage of pancreatic pseudocysts and walled-off necrosis
• ERCP — Bile duct stone extraction; biliary stenting for malignant and benign strictures; sphincterotomy; pancreatic duct interventions; cholangioscopy (SpyGlass)
• Capsule Endoscopy & Device-Assisted Enteroscopy — For small bowel evaluation; double balloon enteroscopy for small bowel lesions and bleeding
• Endoscopic Bariatric Procedures — Intragastric balloon; endoscopic sleeve gastroplasty (ESG) for obesity management
• Chromoendoscopy & Image-Enhanced Endoscopy — NBI, BLI, and LCI for dysplasia detection in IBD and Barrett's esophagus surveillance

Gastrointestinal Motility Disorders

• Achalasia — POEM (preferred); pneumatic dilation; Heller myotomy coordination; botulinum toxin injection
• Gastroparesis — Dietary modification; prokinetics; gastric electrical stimulation; endoscopic pyloromyotomy (G-POEM)
• Functional Dyspepsia — Acid suppression; prokinetics; tricyclic antidepressants; Rome IV criteria-based management
• Irritable Bowel Syndrome (IBS) — Low FODMAP diet; antispasmodics; rifaximin for IBS-D; linaclotide and plecanatide for IBS-C; gut-directed hypnotherapy
• Chronic Constipation — Linaclotide; plecanatide; prucalopride; lubiprostone; anorectal manometry and biofeedback
• Fecal Incontinence — Anorectal manometry; biofeedback; sacral nerve stimulation

Pancreatic Disease

• Acute Pancreatitis — Fluid resuscitation; nutritional support; endoscopic drainage of infected necrosis (VARD, step-up approach); ERCP for biliary pancreatitis
• Chronic Pancreatitis — Pain management; enzyme replacement; endoscopic stone extraction and stricture dilation; EUS-guided celiac plexus block; surgical coordination
• Autoimmune Pancreatitis (AIP) — Type 1 (IgG4-related) and Type 2 AIP; corticosteroids; rituximab for relapsing IgG4-AIP
• Pancreatic Cysts — IPMN surveillance and management; EUS-FNA for cyst fluid analysis; EUS-guided ablation for selected cysts

Other Gastrointestinal Conditions

• Barrett's Esophagus — Surveillance endoscopy; radiofrequency ablation (RFA) for dysplastic Barrett's; ESD for early Barrett's cancer
• Eosinophilic Esophagitis (EoE) — Swallowed topical corticosteroids; dupilumab; elimination diets; esophageal dilation
• Gastrointestinal Bleeding — Endoscopic hemostasis (injection, thermal, mechanical clips, hemostatic powder); TIPS for variceal bleeding; angiographic embolization coordination
• Colorectal Polyps & Cancer Surveillance — Colonoscopy with advanced imaging; polypectomy; post-polypectomy surveillance; hereditary colorectal cancer syndromes
• Celiac Disease — Gluten-free diet; nutritional deficiency correction; refractory celiac disease management

IBD Center: A National Leader

Renji Hospital's IBD center is one of China's most experienced, with a dedicated multidisciplinary team including gastroenterologists, colorectal surgeons, radiologists, pathologists, nutritionists, and psychologists. The center's approach is characterized by:

• Treat-to-target strategy with objective monitoring (endoscopy, fecal calprotectin, CRP)
• Proactive therapeutic drug monitoring for biologic optimization
• Multidisciplinary case conferences for complex IBD
• Dedicated IBD nurse coordinators for patient support
• Active participation in national and international IBD clinical trials

Why International Patients Choose Renji Gastroenterology

• IBD Center of Excellence — One of China's largest IBD cohorts; full range of biologics and small molecules with TDM-guided optimization
• Autoimmune Liver Disease Expertise — Resmetirom for MASH; obeticholic acid, elafibranor, and seladelpar for PBC; PSC endoscopic management
• Advanced Endoscopy Leadership — High-volume ESD, POEM, EUS, and ERCP programs
• FMT Program — One of China's most experienced fecal microbiota transplantation programs
• Liver Transplantation Integration — Seamless coordination with Renji's world-class liver transplantation program for end-stage liver disease
• Cost-Effectiveness — World-class gastroenterology care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your GI diagnosis, endoscopy reports, biopsy results, imaging, liver function tests, and current medications with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate gastroenterologist based on your condition — IBD, autoimmune liver disease, advanced endoscopy, motility, or pancreatic disease.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by Renji's gastroenterology MDT.
5. Priority Scheduling — We secure a consultation and endoscopy slot with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Renji Hospital, and Shanghai airport transfers.
7. On-Site Concierge — Bilingual coordinators accompany you throughout hospital visits, managing registration, translation, and communication.
8. Post-Consultation Follow-Up — Biopsy and test result translation, treatment plan interpretation, and remote follow-up coordination after you return home.

Book a Consultation

If you have Crohn's disease, ulcerative colitis, autoimmune liver disease, a complex GI condition, or require advanced endoscopic procedures — CMCS can arrange a specialist consultation with Renji Hospital's gastroenterology team in Shanghai.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com